Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer
ClinicalTrials.gov · NCT07820358 · Registry updated: 2026-10-01
- Condition / research focus
- Endometrial Atypical Hyperplasia; Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Cancer Stage I; Endometrial Cancer; Fertility-Sparing Treatment (FST); Obesity & Overweight
- Sponsor
- The Methodist Hospital Research Institute
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2027-01-01. Completion: 2031-12-31 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Semaglutide (Wegovy) weekly injection (drug)
- LNG-IUD (Progestin) (device)
- Structured Weight Loss Program (behavioral)
Where the study takes place — 4 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.